Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: SANDOSTATIN LAR

« Back to Dashboard
Sandostatin Lar is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are four patents protecting this drug.

The generic ingredient in SANDOSTATIN LAR is octreotide acetate. There are thirteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the octreotide acetate profile page.

Summary for Tradename: SANDOSTATIN LAR

Suppliers: see list1
2013 Sales:$697,961,000

Clinical Trials for: SANDOSTATIN LAR

Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
Status: Completed Condition: Acromegaly

Ultrasound Guided Sandostatin LAR Injection in Acromegaly
Status: Recruiting Condition: Acromegaly

Effects of Sandostatin LAR® in Acromegaly
Status: Active, not recruiting Condition: Acromegaly

Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
Status: Terminated Condition: Acromegaly

Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis
Status: Completed Condition: Cirrhosis; Portal Hypertension; Esophageal Varices

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis
Status: Completed Condition: Peritoneal Neoplasms; Intestinal Obstruction; Carcinomatosis

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
Status: Completed Condition: Neuroendocrine Carcinoma; Islet Cell Carcinoma

Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anaemia Due to Small Bowel Angiodysplasias
Status: Not yet recruiting Condition: Angiodysplasia; Vascular Malformations; Gastrointestinal Hemorrhage; Anemia

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Status: Active, not recruiting Condition: Well-differentiated Non-pancreatic Neuroendocrine Carcinoma

Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea
Status: Completed Condition: Chemotherapy-induced Diarrhea

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
octreotide acetate
INJECTABLE;INJECTION021008-003Nov 25, 1998RXYes5,639,480*PED<disabled><disabled>
octreotide acetate
INJECTABLE;INJECTION021008-001Nov 25, 1998RXNo5,922,682*PED<disabled>Y<disabled>
octreotide acetate
INJECTABLE;INJECTION021008-003Nov 25, 1998RXYes5,922,338*PED<disabled>Y<disabled>
octreotide acetate
INJECTABLE;INJECTION021008-002Nov 25, 1998RXNo5,922,338*PED<disabled>Y<disabled>
octreotide acetate
INJECTABLE;INJECTION021008-003Nov 25, 1998RXYes5,922,682*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn